Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.235 USD | +9.29% | +16.90% | +17.20% |
07-08 | Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug | MT |
07-01 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to Russell Small Cap Comp Value Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.20% | 198M | |
+25.85% | 46.56B | |
+45.38% | 41.67B | |
+0.91% | 41.16B | |
+30.48% | 32.4B | |
+22.53% | 28.18B | |
-6.35% | 28.1B | |
+49.12% | 14.52B | |
+49.22% | 13.74B | |
+3.49% | 12.17B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating